Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01746420
Recruitment Status : Completed
First Posted : December 11, 2012
Results First Posted : July 2, 2019
Last Update Posted : July 2, 2019
Sponsor:
Information provided by (Responsible Party):
BioMimetic Therapeutics

Brief Summary:
The purpose of this study is to determine whether recombinant human platelet-derived growth factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis elbow).

Condition or disease Intervention/treatment Phase
Lateral Epicondylitis Drug: rhPDGF-BB Injection Drug: Placebo Phase 2

Detailed Description:

Methodology: Randomized, single ascending dose, double-blinded, placebo controlled, multi-center study

Study Center(s): 6

Number of Subjects: 100

Diagnosis and Main Inclusion Criteria: Lateral epicondylitis; male and female subjects 21 -80 years of age

Study Drug, Dose, Regimen:

Dose A: sodium acetate buffer alone - placebo control Dose B: sodium acetate buffer + 0.45 mg rhPDGF-BB Dose C: sodium acetate buffer + 0.75 mg rhPDGF-BB Dose D: sodium acetate buffer + 1.5 mg rhPDGF-BB Dose E: sodium acetate buffer + 3.0 mg rhPDGF-BB

Duration and Route of Administration: Single administration dose by injection into the extensor carpi radialis brevis (ECRB)

Duration of Follow-up: 24 weeks (6 months) post-operative follow-up

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
Actual Study Start Date : December 12, 2012
Actual Primary Completion Date : October 21, 2014
Actual Study Completion Date : October 21, 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Becaplermin

Arm Intervention/treatment
Placebo Comparator: Placebo Control
Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
Drug: Placebo
sodium acetate buffer (0 mg rhPDGF-BB)

Experimental: 0.45 mg rhPDGF-BB
Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

Experimental: 0.75 mg rhPDGF-BB
Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

Experimental: 1.5 mg rhPDGF-BB
Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection

Experimental: 3.0 mg rhPDGF-BB
Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
Drug: rhPDGF-BB Injection
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection




Primary Outcome Measures :
  1. Elbow Pain Assessments (VAS), Treated Subjects [ Time Frame: Baseline, 2, 4, 8, 12, and 24 weeks ]
    Subjects were asked to report current pain level at the fusion site on a 100 mm Visual Analog Scale (with 0 being no pain and 100 being worst pain imaginable).

  2. Disabilities of the Arm, Shoulder and Hand (DASH), Treated Subjects [ Time Frame: Baseline, 4, 8, 12, and 24 weeks ]
    The disabilities of the arm, shoulder and hand (DASH) questionnaire is a self-administered region-specific outcome instrument developed as a measure of self-rated upper-extremity disability and symptoms. The DASH consists mainly of a 30-item disability/symptom scale, scored 0 (no disability) to 100.

  3. Total Score Patient Rated Tennis Elbow Evaluation (PRTEE), All Treated Subjects [ Time Frame: Baseline, 4, 8, 12, and 24 weeks ]

    The Pain and disability measured by the Patient Rated Tennis Elbow Evaluation (PRTEE) is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis (also known as "tennis elbow"). The PRTEE allows patients to rate their levels of tennis elbow pain and disability from 0 to 10, and consists of 2 subscales:

    1. PAIN subscale (0 = no pain, 10 = worst imaginable)

      -Pain - 5 items

    2. FUNCTION subscale (0 = no difficulty, 10 = unable to do)

      • Specific activities - 6 items
      • Usual activities - 4 items

    In addition to the individual subscale scores, a total score can be computed on a scale of 100 (0 = no disability), where pain and functional problems are weighted equally


  4. Grip Strength Test, All Treated Subjects [ Time Frame: Baseline, 4, 8, 12, and 24 weeks ]
    Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis. Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability). The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis. A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position. Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.

  5. Maximum Grip Strength, Treated Subjects [ Time Frame: Baseline, 4, 8, 12, and 24 weeks ]
    A higher grip strength score indicates an improvement. A positive change from baseline indicates an improvement. Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis. Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability). The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis. A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position. Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has signed the Institutional Review Board (IRB) approved Informed Consent Form specific to this study prior to enrollment
  2. Subject has a clinical diagnosis of lateral epicondylitis
  3. Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion
  4. Subject's symptoms have persisted for at least 3 months despite conservative treatment that includes one or combinations of:

    1. Physical therapy
    2. Splinting
    3. Nonsteroidal antiinflammatory drug (NSAID)
    4. Corticosteroid injection
  5. Subject is independent, ambulatory, and can comply with all post-injection evaluations and visits
  6. Subject is 21-80 years of age and considered to be skeletally mature

Exclusion Criteria:

  1. Subject has undergone previous corticosteroid injection therapy to the effected elbow in less than three months prior to enrollment
  2. Subject has received previous Platelet Rich Plasma (PRP) injection to the affected elbow
  3. Subject is deemed to require a corticosteroid injection into the affected elbow during the course of the study
  4. Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage >10mg/day)
  5. Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis
  6. Subject has a positive medical history of any of the following:

    1. medial epicondylitis
    2. radial tunnel syndrome
    3. carpal tunnel syndrome
    4. septic or gouty arthritis
    5. cervical radiculopathy
    6. trauma to the affected elbow within the past 6 weeks
    7. neuromuscular or musculoskeletal deficiency, which limits the ability to perform functional measurement (e.g. grip strength test)
  7. Subject currently has an acute infection at the injection site
  8. Subject has tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or are currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed rhPDGF-BB Injection treatment site
  9. Subject is physically or mentally compromised (e.g. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
  10. Subject has an allergy to yeast-derived products
  11. Subject has received an investigational therapy or approved therapy for investigational use within 30 days of injection procedure or during the follow-up phase of this study
  12. Subject is a prisoner, or is known or suspected to be transient
  13. Subject's condition represents a worker's compensation case
  14. Subject is currently involved in a health-related litigation procedure
  15. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry
  16. Subject is pregnant, or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01746420


Locations
Layout table for location information
United States, Arizona
Arizona Research Center
Phoenix, Arizona, United States, 85023
Tucson Orthopaedic Institute
Tucson, Arizona, United States, 85712
United States, Arkansas
NEA Baptist Clinic
Jonesboro, Arkansas, United States, 72401
United States, Florida
Coastal Orthopedics & Sports Medicine
Bradenton, Florida, United States, 34209
Foundation for Orthopaedic Research and Education
Tampa, Florida, United States, 33637
United States, North Carolina
OrthoCarolina
Charlotte, North Carolina, United States, 28207
Sponsors and Collaborators
BioMimetic Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Edward Akelman, MD Brown University
Layout table for additonal information
Responsible Party: BioMimetic Therapeutics
ClinicalTrials.gov Identifier: NCT01746420    
Other Study ID Numbers: BMTI-2010-02
First Posted: December 11, 2012    Key Record Dates
Results First Posted: July 2, 2019
Last Update Posted: July 2, 2019
Last Verified: June 2019
Keywords provided by BioMimetic Therapeutics:
elbow
Additional relevant MeSH terms:
Layout table for MeSH terms
Tennis Elbow
Elbow Tendinopathy
Tendinopathy
Muscular Diseases
Musculoskeletal Diseases
Arm Injuries
Wounds and Injuries
Tendon Injuries
Becaplermin
Anticoagulants
Angiogenesis Inducing Agents
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs